Proven Process Intensification Strategies for Upstream Bioprocessing
Boost space-time yield and ROI with perfusion process intensification at the N-1 and N stages.
Biologics demand is outpacing upstream capacity, pushing process development and manufacturing teams to find ways to increase output within existing facilities. Perfusion-based intensification offers two proven paths forward: N-stage perfusion to maximize productivity and reduce COG, and N-1 perfusion to accelerate fed-batch timelines through higher-density inoculation. These complementary white papers outline how leading biomanufacturers are using the XCell® ATF System to expand capacity, improve efficiency, and future-proof their upstream operations.
Download the white papers to learn more.
White Paper #1: From Fed-Batch to Perfusion: Unlocking ROI in mAb Manufacturing with Process Intensification
Explore how perfusion-based upstream process intensification using the XCell® ATF System can drive cost reductions, increase space-time yield, and deliver significant return on investment for commercial mAb production.
Key Takeaways:
- Up to 24% lower cost per gram at commercial scale
- 5–10X higher volumetric productivity (space-time yield)
- Run smaller, more flexible facilities with reduced CAPEX and OPEX
- Improved product quality through stable culture conditions
White Paper #2: N-1 Perfusion: The Proven, Practical Gateway to Upstream Process Intensification
N-1 perfusion enables intensified upstream productivity while preserving fed-batch process definitions, regulatory familiarity, and facility fit.
Key Takeaways:
- Up to 20× higher inoculum density enables faster growth and higher fed-batch productivity
- 2–10× increases in volumetric productivity with 20–60% upstream COG reduction
- Proven at commercial scale—500+ sites, 40+ processes, and broad CDMO adoption
Fill out the form to access the white papers.